ASCO Highlights Put Variety in Spotlight

Published: Saturday, Jun 01, 2013

All Eyes on Stocks as ASCO approachesNew data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO), according to industry analysts.

Approximately 30,000 oncology specialists are expected to attend the 49th annual conference, which opened Friday and runs through Tuesday at McCormick Place in Chicago, Illinois.

Kantar Health, which conducts market research and product development for the pharmaceutical industry, has identified approximately 12 abstracts with practice-changing potential that, based on preliminary data, are expected to emerge from the more than 4500 abstracts presented at the meeting. Those abstracts are discussed in the “OBR Conference Preview,” available at the OBR oncology information site ( The abstracts are:

  • Sequencing everolimus (Afinitor) and sunitinib (Sutent) in metastatic renal cell carcinoma; phase II RECORD-3 trial results. Abstract 4504.
  • Talimogene laherparepvec (T-VEC), an immunotherapyagent, versus granulocyte-macrophage colony-stimulating factor in unresected late-stage melanoma; phase III OPTiM trial results. Abstract LBA9008.
  • FOLFIRI plus cetuximab (Erbitux) versus FOLFIRI plus bevacizumab (Avastin) as first-line treatment in KRAS wild-type metastatic colorectal cancer (mCRC); FIRE-3 trial results. Abstract LBA3506.
  • Bevacizumab in newly diagnosed glioblastoma; progression-free survival and quality-of-life results from the phase III AVAglio trial. Kantar analysts noted that results of the RTOG 0825 study in a similar patient population also are likely to be noteworthy. Abstracts 2005 and 1.
  • Lapatinib (Tykerb) in resectable HER2-positive breast cancer; results of the phase III CALGB 40601 study comparing neoadjuvant paclitaxel plus trastuzumab (Herceptin) with and without lapatinib. Abstracts 500 and 501.
  • Everolimus plus trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer; results of the phase III BOLERO-3 trial. Abstract 505.
  • Bevacizumab plus standard chemotherapy in recurrent, metastatic cervical cancer; results of the GOG240 study. Abstract 3.
  • Sorafenib (Nexavar) in radioactive iodine-refractory differentiated thyroid cancer; results of the phase III DECISION trial. Abstract 4.
  • Tamoxifen as adjuvant therapy for hormone receptor-positive breast cancer; results of the aTTom study comparing 10 years versus 5 years of tamoxifen. Abstract 5.
  • Obinutuzumab (GA101) plus chlorambucil in chronic lymphocytic leukemia; stage I results from the CLL11 trial. Abstract 7004.
For the pharmaceutical industry, ASCO marks an important occasion to showcase its research to clinicians and investors alike. Many companies have announced research they intend to spotlight, including:

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication